Design Therapeutics, Inc. (DSGN) News
Track canonical SquawkNews coverage tagged to DSGN, Design Therapeutics, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 3 indexed stories across 2 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
DSGN - Design Therapeutics Provides RESTORE-FA Clinical Development Update and Reports Second Quarter 2026 Financial Results - Click For Rel
DSGN - Design Therapeutics Provides RESTORE-FA Clinical Development Update and Reports Second Quarter 2026 Financial Results
EARNINGS | Aug 03, 2026, 12:01 PM UTC
L
DSGN Design Therapeutics RESULTS: Q2, Q2 operating expenses $22.177M, Q2 Net Income $-20.165M vs. EST $-21.3M, Q2 Operating Income $-22.177M
DSGN Design Therapeutics RESULTS: Q2, Q2 operating expenses $22.177M, Q2 Net Income $-20.165M vs. EST $-21.3M, Q2 Operating Income $-22.177M, Q2 basic EPS $-0.32
EARNINGS | Aug 03, 2026, 12:00 PM UTC
L
Design Therapeutics Starts Patient Dosing In Its Phase 1 Multiple-Ascending Dose Clinical Study Of DT-818 In Adults With Myotonic Dystrophy
Design Therapeutics, Inc. (Nasdaq: DSGN ), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced the initiation of patient dosing in its Phase 1 multiple-
EQUITY | Jun 30, 2026, 12:06 PM UTC